SCHEMBL22608319

SCHEMBL22608319

O=C(OC(=O)C(F)(F)F)c1[nH]nnc1Oc1ccc(C2CCOCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 19/20 0.48
▸ PRKAB2 O43741 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ PRKAG3 Q9UGI9 1/20 0.35
▸ PRKAG2 Q9UGJ0 1/20 0.35
▸ PRKAB1 Q9Y478 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22608460 0.88 HAO1 (0.42) HAO1
Trifluoroacetic Acid SCHEMBL22608318 0.85 HAO1 (0.60) HAO1
SCHEMBL22608188 0.83 HAO1 (0.41) HAO1
SCHEMBL22608371 0.83 HAO1 (0.39) HAO1
SCHEMBL22816847 0.82 HAO1 (0.67) HAO1
SCHEMBL22608130 0.80 HAO1 (0.64) HAO1
SCHEMBL22815997 0.79 HAO1 (0.48) HAO1
SCHEMBL22608184 0.77 HAO1 (0.40) HAO1
SCHEMBL22608385 0.75 HAO1 (0.41) HAO1
SCHEMBL22608627 0.74 HAO1 (0.45) HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
EP-3986863-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2022-04-27 — — EP disclosed
CN-114258390-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2022-03-29 — — CN disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
EP-3732167-A2 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2020-11-04 — — EP disclosed
CN-111788187-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2020-10-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885PRKAB2 4400/4885PRKAG1 3878/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 10/4885PRKAB2 4428/4885PRKAG1 3928/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885PRKAB2 4400/4885PRKAG1 3878/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885PRKAB2 4400/4885PRKAG1 3878/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885PRKAB2 4400/4885PRKAG1 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback